0 XP   0   0   0

BioInvent International AB
Buy, Hold or Sell?

Should you buy, hold or sell Bioinvent?

I guess you are interested in BioInvent International AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Bioinvent

Let's start. I'm going to help you getting a better view of BioInvent International AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is BioInvent International AB even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how BioInvent International AB is doing in the market. If the company is worth buying. The latest step is to find out how other investors value BioInvent International AB. The closing price on 2023-03-23 was kr27.70 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
BioInvent International AB Daily Candlestick Chart
BioInvent International AB Daily Candlestick Chart
Summary









1. Valuation of Bioinvent




Current price per share

kr27.70

2. Growth of Bioinvent




Is Bioinvent growing?

Current yearPrevious yearGrowGrow %
How rich?$163m$127.3m$13.4m9.5%

How much money is Bioinvent making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$4.1m$3.1m?
Net Profit Margin-576.9%-1,108.3%--

How much money comes from the company's main activities?

3. Financial Health of Bioinvent




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  


Richest
#349 / 1230

Most Revenue
#333 / 1230

Most Profit
#291 / 1230

Most Efficient
#891 / 1230


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of BioInvent International AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bioinvent earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Bioinvent to the Biotechnology industry mean.
  • A Net Profit Margin of -356.4% means that kr-3.56 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioInvent International AB:

  • The MRQ is -356.4%. The company is making a huge loss. -2
  • The TTM is -576.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-356.4%TTM-576.9%+220.5%
TTM-576.9%YOY-1,108.3%+531.4%
TTM-576.9%5Y-477.8%-99.2%
5Y-477.8%10Y-581.6%+103.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-356.4%-218.2%-138.2%
TTM-576.9%-341.4%-235.5%
YOY-1,108.3%-319.4%-788.9%
5Y-477.8%-563.8%+86.0%
10Y-581.6%-684.7%+103.1%
1.1.2. Return on Assets

Shows how efficient Bioinvent is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bioinvent to the Biotechnology industry mean.
  • -3.6% Return on Assets means that Bioinvent generated kr-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioInvent International AB:

  • The MRQ is -3.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.6%TTM-0.8%-2.8%
TTM-0.8%YOY-2.3%+1.5%
TTM-0.8%5Y-10.4%+9.6%
5Y-10.4%10Y-13.5%+3.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.6%-12.5%+8.9%
TTM-0.8%-12.2%+11.4%
YOY-2.3%-11.5%+9.2%
5Y-10.4%-15.2%+4.8%
10Y-13.5%-17.5%+4.0%
1.1.3. Return on Equity

Shows how efficient Bioinvent is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bioinvent to the Biotechnology industry mean.
  • -3.8% Return on Equity means Bioinvent generated kr-0.04 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioInvent International AB:

  • The MRQ is -3.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -0.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.8%TTM-0.8%-3.0%
TTM-0.8%YOY-2.3%+1.5%
TTM-0.8%5Y-13.7%+12.8%
5Y-13.7%10Y-20.6%+7.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.8%-15.4%+11.6%
TTM-0.8%-16.0%+15.2%
YOY-2.3%-13.2%+10.9%
5Y-13.7%-19.7%+6.0%
10Y-20.6%-20.7%+0.1%

1.2. Operating Efficiency of BioInvent International AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bioinvent is operating .

  • Measures how much profit Bioinvent makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bioinvent to the Biotechnology industry mean.
  • An Operating Margin of -356.4% means the company generated kr-3.56  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioInvent International AB:

  • The MRQ is -356.4%. The company is operating very inefficient. -2
  • The TTM is -576.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-356.4%TTM-576.9%+220.5%
TTM-576.9%YOY-1,108.3%+531.4%
TTM-576.9%5Y-477.8%-99.2%
5Y-477.8%10Y-582.6%+104.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-356.4%-223.5%-132.9%
TTM-576.9%-321.4%-255.5%
YOY-1,108.3%-351.6%-756.7%
5Y-477.8%-547.5%+69.7%
10Y-582.6%-672.0%+89.4%
1.2.2. Operating Ratio

Measures how efficient Bioinvent is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.86 means that the operating costs are kr4.86 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of BioInvent International AB:

  • The MRQ is 4.859. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.847. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.859TTM6.847-1.989
TTM6.847YOY12.063-5.216
TTM6.8475Y5.795+1.052
5Y5.79510Y6.866-1.071
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8593.387+1.472
TTM6.8474.100+2.747
YOY12.0634.678+7.385
5Y5.7957.290-1.495
10Y6.8668.504-1.638

1.3. Liquidity of BioInvent International AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bioinvent is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 23.60 means the company has kr23.60 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of BioInvent International AB:

  • The MRQ is 23.604. The company is very able to pay all its short-term debts. +2
  • The TTM is 19.450. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ23.604TTM19.450+4.154
TTM19.450YOY23.773-4.323
TTM19.4505Y11.646+7.805
5Y11.64610Y7.746+3.900
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.6044.891+18.713
TTM19.4505.355+14.095
YOY23.7736.134+17.639
5Y11.6466.378+5.268
10Y7.7466.497+1.249
1.3.2. Quick Ratio

Measures if Bioinvent is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bioinvent to the Biotechnology industry mean.
  • A Quick Ratio of 33.19 means the company can pay off kr33.19 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioInvent International AB:

  • The MRQ is 33.194. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 24.728. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ33.194TTM24.728+8.466
TTM24.728YOY23.602+1.127
TTM24.7285Y12.774+11.954
5Y12.77410Y8.284+4.490
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ33.1944.353+28.841
TTM24.7284.977+19.751
YOY23.6025.599+18.003
5Y12.7745.960+6.814
10Y8.2845.920+2.364

1.4. Solvency of BioInvent International AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bioinvent assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bioinvent to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Bioinvent assets are financed with 4.0% credit (debt) and the remaining percentage (100% - 4.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioInvent International AB:

  • The MRQ is 0.040. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.053. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.040TTM0.053-0.013
TTM0.053YOY0.053+0.000
TTM0.0535Y0.159-0.105
5Y0.15910Y0.243-0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0400.290-0.250
TTM0.0530.282-0.229
YOY0.0530.279-0.226
5Y0.1590.374-0.215
10Y0.2430.410-0.167
1.4.2. Debt to Equity Ratio

Measures if Bioinvent is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bioinvent to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.2% means that company has kr0.04 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioInvent International AB:

  • The MRQ is 0.042. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.056. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.042TTM0.056-0.014
TTM0.056YOY0.056+0.000
TTM0.0565Y0.207-0.151
5Y0.20710Y0.403-0.196
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0420.334-0.292
TTM0.0560.341-0.285
YOY0.0560.274-0.218
5Y0.2070.418-0.211
10Y0.4030.451-0.048

2. Market Valuation of BioInvent International AB

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Bioinvent generates.

  • Above 15 is considered overpriced but always compare Bioinvent to the Biotechnology industry mean.
  • A PE ratio of -48.89 means the investor is paying kr-48.89 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioInvent International AB:

  • The EOD is -28.540. Company is losing money. -2
  • The MRQ is -48.889. Company is losing money. -2
  • The TTM is -30.395. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-28.540MRQ-48.889+20.349
MRQ-48.889TTM-30.395-18.494
TTM-30.395YOY-9.319-21.075
TTM-30.3955Y-10.072-20.323
5Y-10.07210Y2.718-12.790
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-28.540-6.014-22.526
MRQ-48.889-7.783-41.106
TTM-30.395-10.284-20.111
YOY-9.319-21.956+12.637
5Y-10.072-17.992+7.920
10Y2.718-18.154+20.872
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Bioinvent.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of BioInvent International AB:

  • The MRQ is 128.175. Seems overpriced? -1
  • The TTM is 9.507. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ128.175TTM9.507+118.668
TTM9.507YOY-10.725+20.232
TTM9.5075Y-3.039+12.546
5Y-3.03910Y2.188-5.228
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ128.175-5.754+133.929
TTM9.507-7.949+17.456
YOY-10.725-15.778+5.053
5Y-3.039-13.905+10.866
10Y2.188-13.164+15.352

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bioinvent is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.85 means the investor is paying kr1.85 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of BioInvent International AB:

  • The EOD is 1.082. Good. +1
  • The MRQ is 1.854. Good. +1
  • The TTM is 2.209. Good. +1
Trends
Current periodCompared to+/- 
EOD1.082MRQ1.854-0.772
MRQ1.854TTM2.209-0.355
TTM2.209YOY2.553-0.344
TTM2.2095Y1.409+0.800
5Y1.40910Y2.450-1.041
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.0821.758-0.676
MRQ1.8542.073-0.219
TTM2.2092.615-0.406
YOY2.5534.056-1.503
5Y1.4093.689-2.280
10Y2.4503.866-1.416
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BioInvent International AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--3.2960.907+263%3.008+10%1.156+185%0.614+437%
Book Value Growth--1.1481.043+10%1.291-11%1.247-8%1.308-12%
Book Value Per Share--25.59521.154+21%19.992+28%10.028+155%5.711+348%
Book Value Per Share Growth--1.1481.053+9%1.291-11%1.249-8%1.309-12%
Current Ratio--23.60419.450+21%23.773-1%11.646+103%7.746+205%
Debt To Asset Ratio--0.0400.053-24%0.053-23%0.159-75%0.243-83%
Debt To Equity Ratio--0.0420.056-25%0.056-25%0.207-80%0.403-90%
Dividend Per Share----0%-0%-0%-0%
Eps---0.971-0.108-89%-0.650-33%-0.456-53%-0.347-64%
Eps Growth---0.3811.502-125%0.565-168%0.957-140%-1.203+215%
Free Cash Flow Per Share--2.606-0.152+106%-0.581+122%-0.451+117%-0.376+114%
Free Cash Flow Per Share Growth--4.6511.891+146%0.683+581%0.949+390%0.396+1074%
Free Cash Flow To Equity Per Share--6.8350.888+670%3.052+124%1.213+463%0.890+668%
Free Cash Flow To Equity Per Share Growth--8.7852.924+200%2.720+223%2.313+280%11.048-20%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---42.379--------
Intrinsic Value_10Y_min---74.367--------
Intrinsic Value_1Y_max---1.137--------
Intrinsic Value_1Y_min---2.621--------
Intrinsic Value_3Y_max---5.787--------
Intrinsic Value_3Y_min---12.106--------
Intrinsic Value_5Y_max---13.293--------
Intrinsic Value_5Y_min---26.156--------
Net Profit Margin---3.564-5.769+62%-11.083+211%-4.778+34%-5.816+63%
Operating Margin---3.564-5.769+62%-11.083+211%-4.778+34%-5.826+63%
Operating Ratio--4.8596.847-29%12.063-60%5.795-16%6.866-29%
Pb Ratio1.082-71%1.8542.209-16%2.553-27%1.409+32%2.450-24%
Pe Ratio-28.540+42%-48.889-30.395-38%-9.319-81%-10.072-79%2.718-1899%
Peg Ratio--128.1759.507+1248%-10.725+108%-3.039+102%2.188+5757%
Price Per Share27.700-71%47.45045.733+4%46.745+2%19.505+143%11.112+327%
Price To Total Gains Ratio8.404-71%14.3979.689+49%-16.751+216%-0.081+101%10.386+39%
Profit Growth---0.3811.493-126%0.565-168%0.956-140%-1.204+216%
Quick Ratio--33.19424.728+34%23.602+41%12.774+160%8.284+301%
Return On Assets---0.036-0.008-78%-0.023-38%-0.104+185%-0.135+272%
Return On Equity---0.038-0.008-78%-0.023-38%-0.137+260%-0.206+444%
Revenue Growth--0.0665.341-99%1.888-96%2.143-97%3.195-98%
Total Gains Per Share--3.2960.907+263%3.008+10%1.156+185%0.614+437%
Total Gains Per Share Growth--1.2900.382+238%2.547-49%5.188-75%19.155-93%
Usd Book Value--163036271.200140793349.400+16%127348507.000+28%65085241.760+150%36980738.740+341%
Usd Book Value Change Per Share--0.3190.088+263%0.291+10%0.112+185%0.059+437%
Usd Book Value Per Share--2.4782.048+21%1.935+28%0.971+155%0.553+348%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.094-0.010-89%-0.063-33%-0.044-53%-0.034-64%
Usd Free Cash Flow--16602845.600-1318077.200+108%-3698098.800+122%-2940227.400+118%-2432780.020+115%
Usd Free Cash Flow Per Share--0.252-0.015+106%-0.056+122%-0.044+117%-0.036+114%
Usd Free Cash Flow To Equity Per Share--0.6620.086+670%0.295+124%0.117+463%0.086+668%
Usd Price Per Share2.681-71%4.5934.427+4%4.525+2%1.888+143%1.076+327%
Usd Profit---6182422.400-1038857.600-83%-4142168.800-33%-2971910.040-52%-2245784.200-64%
Usd Revenue--1734656.0007511413.800-77%2740020.800-37%2991439.440-42%2116774.000-18%
Usd Total Gains Per Share--0.3190.088+263%0.291+10%0.112+185%0.059+437%
 EOD+2 -3MRQTTM+28 -11YOY+24 -155Y+26 -1310Y+28 -11

3.2. Fundamental Score

Let's check the fundamental score of BioInvent International AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-28.540
Price to Book Ratio (EOD)Between0-11.082
Net Profit Margin (MRQ)Greater than0-3.564
Operating Margin (MRQ)Greater than0-3.564
Quick Ratio (MRQ)Greater than133.194
Current Ratio (MRQ)Greater than123.604
Debt to Asset Ratio (MRQ)Less than10.040
Debt to Equity Ratio (MRQ)Less than10.042
Return on Equity (MRQ)Greater than0.15-0.038
Return on Assets (MRQ)Greater than0.05-0.036
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of BioInvent International AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose26.950
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in SEK. All numbers in thousands.

Summary
Total Assets1,755,102
Total Liabilities70,843
Total Stockholder Equity1,684,259
 As reported
Total Liabilities 70,843
Total Stockholder Equity+ 1,684,259
Total Assets = 1,755,102

Assets

Total Assets1,755,102
Total Current Assets1,269,550
Long-term Assets1,269,550
Total Current Assets
Cash And Cash Equivalents 696,315
Short-term Investments 527,049
Net Receivables 34,948
Inventory 11,238
Total Current Assets  (as reported)1,269,550
Total Current Assets  (calculated)1,269,550
+/-0
Long-term Assets
Property Plant Equipment 44,580
Long-term Assets Other 527,049
Long-term Assets  (as reported)485,552
Long-term Assets  (calculated)571,629
+/- 86,077

Liabilities & Shareholders' Equity

Total Current Liabilities53,785
Long-term Liabilities17,058
Total Stockholder Equity1,684,259
Total Current Liabilities
Short-term Debt 6,521
Other Current Liabilities 47,264
Total Current Liabilities  (as reported)53,785
Total Current Liabilities  (calculated)53,785
+/-0
Long-term Liabilities
Long term Debt Total 17,058
Long-term Liabilities  (as reported)17,058
Long-term Liabilities  (calculated)17,058
+/-0
Total Stockholder Equity
Common Stock1,684,259
Total Stockholder Equity (as reported)1,684,259
Total Stockholder Equity (calculated)1,684,259
+/-0
Other
Cash and Short Term Investments 1,223,364
Common Stock Shares Outstanding 58,548
Liabilities and Stockholders Equity 1,755,102
Net Debt -672,736
Net Tangible Assets 1,684,259
Net Working Capital 1,215,765
Short Long Term Debt Total 23,579



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-06-302002-12-312002-06-302001-12-312001-06-30
> Total Assets 
471,666
410,551
473,622
435,537
393,781
343,185
324,132
287,941
265,574
238,405
212,042
180,182
137,504
266,344
227,558
203,104
168,639
148,332
235,574
193,965
293,852
271,001
219,840
370,870
354,777
295,427
260,375
206,458
158,485
126,246
221,371
215,649
182,938
138,030
190,563
280,629
240,164
205,757
161,835
212,895
180,780
116,543
89,400
57,733
55,636
81,437
54,239
119,254
100,837
74,108
49,352
91,339
69,193
54,447
58,088
243,005
217,295
276,298
238,375
220,194
193,930
170,047
227,213
184,572
144,797
120,400
141,222
316,632
273,798
226,111
194,337
250,820
703,539
802,640
1,626,515
1,588,200
1,520,183
1,447,311
1,380,744
1,556,741
1,755,102
1,755,1021,556,7411,380,7441,447,3111,520,1831,588,2001,626,515802,640703,539250,820194,337226,111273,798316,632141,222120,400144,797184,572227,213170,047193,930220,194238,375276,298217,295243,00558,08854,44769,19391,33949,35274,108100,837119,25454,23981,43755,63657,73389,400116,543180,780212,895161,835205,757240,164280,629190,563138,030182,938215,649221,371126,246158,485206,458260,375295,427354,777370,870219,840271,001293,852193,965235,574148,332168,639203,104227,558266,344137,504180,182212,042238,405265,574287,941324,132343,185393,781435,537473,622410,551471,666
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
107,255
204,053
199,982
168,521
123,783
174,888
265,857
226,913
192,900
150,348
202,722
171,981
109,767
83,346
52,356
50,984
77,509
50,813
107,330
89,170
67,307
42,948
89,623
67,779
53,124
55,848
240,577
212,052
270,650
229,502
209,274
179,998
150,801
208,339
165,151
126,085
102,367
102,730
279,696
239,179
193,106
163,143
220,250
674,346
773,044
1,598,363
1,538,141
1,279,729
1,116,019
1,058,222
1,273,231
1,269,550
1,269,5501,273,2311,058,2221,116,0191,279,7291,538,1411,598,363773,044674,346220,250163,143193,106239,179279,696102,730102,367126,085165,151208,339150,801179,998209,274229,502270,650212,052240,57755,84853,12467,77989,62342,94867,30789,170107,33050,81377,50950,98452,35683,346109,767171,981202,722150,348192,900226,913265,857174,888123,783168,521199,982204,053107,25500000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74,036
29,310
19,774
33,059
36,952
27,779
15,533
18,953
92,343
101,556
93,696
96,622
100,061
77,124
39,764
39,942
64,745
41,776
74,297
70,394
45,627
25,747
62,708
50,534
39,973
41,442
224,459
196,418
226,114
216,031
192,774
162,551
103,700
78,054
144,703
107,097
68,851
28,458
210,343
183,901
153,975
117,127
182,284
642,098
729,270
1,577,077
1,509,661
1,256,516
910,755
769,793
591,224
696,315
696,315591,224769,793910,7551,256,5161,509,6611,577,077729,270642,098182,284117,127153,975183,901210,34328,45868,851107,097144,70378,054103,700162,551192,774216,031226,114196,418224,45941,44239,97350,53462,70825,74745,62770,39474,29741,77664,74539,94239,76477,124100,06196,62293,696101,55692,34318,95315,53327,77936,95233,05919,77429,31074,03600000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,984
149,804
118,900
110,825
69,118
40,040
238,203
197,664
81,622
36,486
92,552
55,915
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,060
30,098
30,098
30,135
0
0
0
0
0
0
0
0
0
0
0
0
172,074
236,948
386,813
527,049
527,049386,813236,948172,07400000000000030,13530,09830,09830,0600000000000000000000055,91592,55236,48681,622197,664238,20340,04069,118110,825118,900149,8049,98400000000000000000000000000000
       Net Receivables 
13,562
22,385
26,585
15,120
15,229
5,943
20,856
13,862
16,505
12,566
17,656
13,772
14,842
23,740
21,111
25,124
15,831
15,317
26,300
17,785
29,449
21,998
32,608
215,654
68,254
46,494
39,698
30,088
20,458
15,304
23,782
58,360
22,665
12,116
106,174
11,699
9,968
12,363
12,054
16,257
19,227
6,957
6,099
12,468
10,774
10,963
8,860
32,954
18,671
19,995
17,115
23,693
14,334
11,057
12,218
16,040
14,352
40,884
13,246
14,215
12,821
12,888
97,852
17,745
16,880
28,769
71,436
63,521
44,485
33,299
40,202
32,393
28,042
39,231
14,395
16,027
10,084
13,457
37,996
283,020
34,948
34,948283,02037,99613,45710,08416,02714,39539,23128,04232,39340,20233,29944,48563,52171,43628,76916,88017,74597,85212,88812,82114,21513,24640,88414,35216,04012,21811,05714,33423,69317,11519,99518,67132,9548,86010,96310,77412,4686,0996,95719,22716,25712,05412,3639,96811,699106,17412,11622,66558,36023,78215,30420,45830,08839,69846,49468,254215,65432,60821,99829,44917,78526,30015,31715,83125,12421,11123,74014,84213,77217,65612,56616,50513,86220,8565,94315,22915,12026,58522,38513,562
       Other Current Assets 
0
7,432
0
10,464
0
4,963
0
0
0
7,175
0
0
0
2,749
0
0
0
2,097
0
0
0
1,613
0
0
0
5,358
0
0
0
21,198
23,782
58,360
22,665
17,030
106,174
11,699
9,968
18,653
12,054
16,257
19,227
9,457
6,099
12,468
10,774
12,559
8,860
32,954
18,671
21,619
17,115
23,693
14,334
12,687
12,218
16,040
14,352
42,618
13,246
14,215
12,821
14,655
97,852
17,745
16,880
30,566
71,436
63,521
44,485
33,751
40,202
32,393
28,042
39,695
14,395
16,027
10,084
16,342
37,996
283,020
34,948
34,948283,02037,99616,34210,08416,02714,39539,69528,04232,39340,20233,75144,48563,52171,43630,56616,88017,74597,85214,65512,82114,21513,24642,61814,35216,04012,21812,68714,33423,69317,11521,61918,67132,9548,86012,55910,77412,4686,0999,45719,22716,25712,05418,6539,96811,699106,17417,03022,66558,36023,78221,1980005,3580001,6130002,0970002,7490007,1750004,963010,46407,4320
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,991
17,318
15,667
14,417
14,247
15,675
14,772
13,251
12,857
11,487
10,173
8,799
6,776
6,054
5,377
4,652
3,928
3,426
11,924
11,667
6,801
6,404
1,716
1,414
1,323
2,240
2,428
5,243
5,648
8,873
10,920
13,932
19,246
18,874
19,421
18,712
18,033
38,492
36,936
34,619
33,005
31,194
30,570
29,193
29,596
28,152
50,059
240,454
331,292
322,522
283,510
485,552
485,552283,510322,522331,292240,45450,05928,15229,59629,19330,57031,19433,00534,61936,93638,49218,03318,71219,42118,87419,24613,93210,9208,8735,6485,2432,4282,2401,3231,4141,7166,4046,80111,66711,9243,4263,9284,6525,3776,0546,7768,79910,17311,48712,85713,25114,77215,67514,24714,41715,66717,31818,99100000000000000000000000000000
       Property Plant Equipment 
34,608
40,508
40,810
43,816
39,307
34,548
31,517
28,525
25,463
22,440
19,715
17,004
16,526
11,392
13,829
15,219
17,638
13,444
15,246
14,528
13,310
12,281
14,567
15,451
16,217
16,427
15,041
14,199
13,217
11,969
11,569
11,192
10,653
10,445
12,923
12,320
11,099
11,005
9,935
8,921
7,847
6,776
6,054
5,377
4,652
3,928
3,426
2,924
2,667
2,301
1,904
1,716
1,414
1,323
2,240
2,428
5,243
5,648
8,873
10,920
13,932
19,246
18,187
19,421
18,712
18,033
38,492
36,936
34,619
33,005
31,194
30,570
29,193
29,596
28,152
50,059
51,652
49,084
48,402
46,971
44,580
44,58046,97148,40249,08451,65250,05928,15229,59629,19330,57031,19433,00534,61936,93638,49218,03318,71219,42118,18719,24613,93210,9208,8735,6485,2432,4282,2401,3231,4141,7161,9042,3012,6672,9243,4263,9284,6525,3776,0546,7767,8478,9219,93511,00511,09912,32012,92310,44510,65311,19211,56911,96913,21714,19915,04116,42716,21715,45114,56712,28113,31014,52815,24613,44417,63815,21913,82911,39216,52617,00419,71522,44025,46328,52531,51734,54839,30743,81640,81040,50834,608
       Intangible Assets 
0
0
9,050
19,726
16,981
19,357
22,749
20,522
18,294
16,066
13,839
22,852
20,834
26,489
24,559
22,665
20,771
18,877
16,983
15,396
13,964
12,532
11,100
9,668
13,989
12,384
10,843
9,570
8,296
7,022
5,749
4,475
3,764
3,052
2,752
2,452
2,152
1,852
1,552
1,252
952
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000009521,2521,5521,8522,1522,4522,7523,0523,7644,4755,7497,0228,2969,57010,84312,38413,9899,66811,10012,53213,96415,39616,98318,87720,77122,66524,55926,48920,83422,85213,83916,06618,29420,52222,74919,35716,98119,7269,05000
       Other Assets 
0
0
9,050
19,726
16,981
19,357
22,749
20,522
18,294
16,066
13,839
22,852
20,834
30,183
24,559
22,665
20,771
21,674
16,983
15,396
13,964
14,433
11,100
9,668
13,989
12,384
10,843
9,570
8,296
7,022
5,749
4,475
3,764
3,052
2,752
2,452
2,152
1,852
1,552
1,252
952
0
0
0
0
0
0
9,000
9,000
4,500
4,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,828
13,890
16,779
16,762
16,905
17,726
20,928
0
22,494
22,589
21,723
21,72322,58922,494020,92817,72616,90516,76216,77913,89015,82800000000000000000004,5004,5009,0009,0000000009521,2521,5521,8522,1522,4522,7523,0523,7644,4755,7497,0228,2969,57010,84312,38413,9899,66811,10014,43313,96415,39616,98321,67420,77122,66524,55930,18320,83422,85213,83916,06618,29420,52222,74919,35716,98119,7269,05000
> Total Liabilities 
62,244
22,135
57,128
41,287
43,594
38,228
39,067
27,445
28,981
25,727
25,343
45,803
33,132
47,344
38,725
46,241
33,453
38,180
52,624
43,205
41,623
56,883
45,706
62,894
78,699
64,129
63,584
62,955
57,306
70,613
58,756
75,115
67,013
63,839
56,606
49,001
43,618
67,805
60,203
106,526
111,727
68,919
56,033
33,778
27,105
32,430
24,128
28,091
19,946
21,680
18,662
18,243
18,695
24,993
28,346
30,313
33,112
45,861
30,299
35,597
30,539
39,822
41,552
42,030
24,446
32,779
51,382
69,315
63,343
56,675
57,881
57,402
49,739
59,141
61,292
80,082
74,688
80,324
81,457
89,367
70,843
70,84389,36781,45780,32474,68880,08261,29259,14149,73957,40257,88156,67563,34369,31551,38232,77924,44642,03041,55239,82230,53935,59730,29945,86133,11230,31328,34624,99318,69518,24318,66221,68019,94628,09124,12832,43027,10533,77856,03368,919111,727106,52660,20367,80543,61849,00156,60663,83967,01375,11558,75670,61357,30662,95563,58464,12978,69962,89445,70656,88341,62343,20552,62438,18033,45346,24138,72547,34433,13245,80325,34325,72728,98127,44539,06738,22843,59441,28757,12822,13562,244
   > Total Current Liabilities 
62,244
22,135
57,128
41,287
43,594
38,228
39,067
27,445
28,981
25,727
25,343
45,803
33,132
47,344
38,725
46,241
33,453
38,180
52,624
43,205
41,623
56,883
45,706
62,894
78,699
64,129
63,584
62,955
57,306
70,613
58,756
75,115
67,013
63,839
56,606
49,001
43,618
67,805
60,203
106,526
111,727
68,919
56,033
33,778
27,105
32,430
24,128
28,091
19,946
21,680
18,662
18,243
18,695
24,993
28,346
30,313
33,112
45,861
30,299
35,597
30,539
39,822
41,552
42,030
24,446
32,779
37,639
56,987
52,438
47,203
49,851
50,823
44,620
53,509
57,307
54,947
51,684
58,792
61,407
70,808
53,785
53,78570,80861,40758,79251,68454,94757,30753,50944,62050,82349,85147,20352,43856,98737,63932,77924,44642,03041,55239,82230,53935,59730,29945,86133,11230,31328,34624,99318,69518,24318,66221,68019,94628,09124,12832,43027,10533,77856,03368,919111,727106,52660,20367,80543,61849,00156,60663,83967,01375,11558,75670,61357,30662,95563,58464,12978,69962,89445,70656,88341,62343,20552,62438,18033,45346,24138,72547,34433,13245,80325,34325,72728,98127,44539,06738,22843,59441,28757,12822,13562,244
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,057
6,057
6,057
6,057
6,057
6,057
6,057
5,972
6,183
6,183
6,939
6,835
6,731
6,626
6,521
6,5216,6266,7316,8356,9396,1836,1835,9726,0576,0576,0576,0576,0576,0576,057000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,057
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000006,057000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
6,933
0
12,861
0
6,057
0
0
0
8,582
0
0
0
14,795
0
0
0
12,772
0
0
0
14,115
0
0
0
12,784
0
0
0
16,510
0
0
0
17,282
0
0
0
19,457
0
0
0
13,349
0
0
0
9,446
0
0
0
7,588
0
0
0
9,647
0
0
0
10,291
0
0
0
14,171
0
0
0
10,821
0
0
0
14,361
0
0
0
16,913
0
0
0
19,720
0
0
0
00019,72000016,91300014,36100010,82100014,17100010,2910009,6470007,5880009,44600013,34900019,45700017,28200016,51000012,78400014,11500012,77200014,7950008,5820006,057012,86106,9330
       Other Current Liabilities 
0
15,202
0
28,426
0
32,171
0
0
0
17,145
25,343
45,803
33,132
32,549
38,725
46,241
33,453
25,408
52,624
43,205
41,623
42,768
45,706
62,894
78,699
51,345
63,584
62,955
57,306
54,103
58,756
75,115
67,013
46,557
56,606
49,001
43,618
48,348
60,203
106,526
111,727
55,570
56,033
33,778
27,105
22,984
24,128
28,091
19,946
14,092
18,662
18,243
18,695
15,346
28,346
30,313
33,112
35,570
30,299
35,597
30,539
25,651
41,552
42,030
24,446
21,958
31,582
50,930
46,381
26,785
43,794
44,766
38,563
30,624
51,124
48,764
44,745
32,237
54,676
64,182
47,264
47,26464,18254,67632,23744,74548,76451,12430,62438,56344,76643,79426,78546,38150,93031,58221,95824,44642,03041,55225,65130,53935,59730,29935,57033,11230,31328,34615,34618,69518,24318,66214,09219,94628,09124,12822,98427,10533,77856,03355,570111,727106,52660,20348,34843,61849,00156,60646,55767,01375,11558,75654,10357,30662,95563,58451,34578,69962,89445,70642,76841,62343,20552,62425,40833,45346,24138,72532,54933,13245,80325,34317,14500032,171028,426015,2020
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,743
12,328
10,905
9,472
8,030
6,579
5,119
5,632
3,985
25,135
23,004
21,532
20,050
18,559
17,058
17,05818,55920,05021,53223,00425,1353,9855,6325,1196,5798,0309,47210,90512,32813,743000000000000000000000000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,119
5,632
3,985
25,135
23,004
21,532
20,050
18,559
17,058
17,05818,55920,05021,53223,00425,1353,9855,6325,119000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
409,422
388,416
416,494
394,250
350,187
304,957
285,065
260,496
236,593
212,678
186,699
134,379
104,372
219,000
188,833
156,863
135,186
110,152
182,950
150,760
252,229
214,118
174,134
307,976
276,078
231,298
196,791
143,503
101,179
55,633
162,615
140,534
115,925
74,191
133,957
231,628
196,546
137,952
101,632
106,369
69,053
47,624
33,367
23,955
28,531
49,007
30,111
91,163
80,891
52,428
30,690
73,096
50,498
29,454
29,742
212,692
184,183
230,437
208,076
184,597
163,391
130,225
185,661
142,542
120,351
87,621
89,840
247,317
210,455
169,436
136,456
193,418
653,800
743,499
1,565,223
1,508,118
1,445,495
1,366,987
1,299,287
1,467,374
1,684,259
1,684,2591,467,3741,299,2871,366,9871,445,4951,508,1181,565,223743,499653,800193,418136,456169,436210,455247,31789,84087,621120,351142,542185,661130,225163,391184,597208,076230,437184,183212,69229,74229,45450,49873,09630,69052,42880,89191,16330,11149,00728,53123,95533,36747,62469,053106,369101,632137,952196,546231,628133,95774,191115,925140,534162,61555,633101,179143,503196,791231,298276,078307,976174,134214,118252,229150,760182,950110,152135,186156,863188,833219,000104,372134,379186,699212,678236,593260,496285,065304,957350,187394,250416,494388,416409,422
   Common Stock
0
14,072
0
14,738
0
14,738
0
0
0
14,738
14,738
14,738
14,738
23,580
188,833
156,863
135,186
23,580
182,950
150,760
252,229
27,830
174,134
307,976
276,078
27,830
196,791
143,503
101,179
27,830
30,500
140,534
115,925
30,548
133,957
231,628
196,546
33,603
101,632
106,369
69,053
36,963
33,367
23,955
28,531
6,801
30,111
91,163
80,891
9,023
30,690
73,096
50,498
13,033
29,742
212,692
184,183
24,376
208,076
184,597
163,391
24,376
185,623
142,542
120,351
28,064
89,840
247,317
210,455
40,142
136,456
193,418
653,800
78,752
1,565,223
1,508,118
1,445,495
11,694
1,299,287
1,467,374
1,684,259
1,684,2591,467,3741,299,28711,6941,445,4951,508,1181,565,22378,752653,800193,418136,45640,142210,455247,31789,84028,064120,351142,542185,62324,376163,391184,597208,07624,376184,183212,69229,74213,03350,49873,09630,6909,02380,89191,16330,1116,80128,53123,95533,36736,96369,053106,369101,63233,603196,546231,628133,95730,548115,925140,53430,50027,830101,179143,503196,79127,830276,078307,976174,13427,830252,229150,760182,95023,580135,186156,863188,83323,58014,73814,73814,73814,73800014,738014,738014,0720
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
805,146
0
0
0
946,831
0
0
0
1,072,053
0
0
0
1,165,215
0
0
0
1,214,750
0
0
0
1,269,852
0
0
0
1,333,433
0
0
0
1,585,602
0
0
0
1,585,602
0
0
0
1,662,246
0
0
0
1,870,237
136,456
193,418
653,800
2,482,064
1,565,223
1,508,118
1,445,495
3,449,916
1,299,287
1,467,374
1,684,259
1,684,2591,467,3741,299,2873,449,9161,445,4951,508,1181,565,2232,482,064653,800193,418136,4561,870,2370001,662,2460001,585,6020001,585,6020001,333,4330001,269,8520001,214,7500001,165,2150001,072,053000946,831000805,14600000000000000000000000000000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.